L'intérêt à découvert pour Tevogen Bio Holdings donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Tevogen Bio Holdings. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Tevogen Bio Holdings (NASDAQ:TVGN) Stock, Rapport sur les intérêts à découvert

Tevogen Bio Holdings

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Inc

WIIM

CAT stock has given up its prior loss. Caterpillar shares were trading lower after the company reported worse-than-expected Q1 financial results.

News

Guidance

Automatic Data Processing Raises FY2025 Adj EPS Guidance from $9.82-$10.01 to $9.91-$10.01 vs $9.94 Est; Affirms FY2025 Sales Guidance of $20.36B-$20.55B vs $20.44B Est

Urban Edge Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UE#NYSE">UE</a>) affirms FY2025 FFO guidance from $1.37-$1.42 to $1.37-$1.42 vs $1.40 analyst estimate..

Urban Edge Props Affirms FY2025 FFO Guidance of $1.37-$1.42 vs $1.40 Est

JP Morgan analyst Tami Zakaria downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Overweight to Neutral and lowers the price target from $105 to $90.

Downgrades

Price Target

Analyst Ratings

PCAR

JP Morgan Downgrades PACCAR to Neutral, Lowers Price Target to $90

AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) raises FY2025 Adj EPS guidance from $8.50-$9.50 to $9.30-$10.30 vs $11.66 analyst estimate..

AerCap Holdings Raises FY2025 Adj EPS Guidance from $8.50-$9.50 to $9.30-$10.30 vs $11.66 Est

IMAB

I-Mab's Givastomig Combo Study Accepted For Mini-Oral Presentation At ESMO GI Cancers Congress 2025

Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) affirms FY2025 Adj EPS guidance from $4.16-$4.35 to $4.16-$4.35 vs $4.17 analyst estimate. Affirms FY2025 sales outlook from $1.11 billion-$1.13 billion to $1.11 billion-$1.13 billion vs $1.11 billion estimate.

BLKB

Blackbaud Affirms FY2025 Adj EPS Guidance of $4.16-$4.35 vs $4.17 Est; Affirms FY2025 Sales Guidance of $1.11B-$1.13B vs $1.11B Est

Vita Coco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCO#NASDAQ">COCO</a>) affirms FY2025 sales outlook from $555.00 million-$570.00 million to $555.00 million-$570.00 million vs $568.75 million estimate.

COCO

Vita Coco Affirms FY2025 Sales Guidance of $555.00M-$570.00M vs $568.75M Est

Urban Edge Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UE#NYSE">UE</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.34 by 2.94 percent. This is a 6.06 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $118.17 million which missed the analyst consensus estimate of $119.05 million by 0.74 percent. This is a 7.79 percent increase over sales of $109.63 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Urban Edge Props Q1 FFO $0.35 Beats $0.34 Estimate, Sales $118.17M Miss $119.05M Estimate

Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>), a global leader of agricultural commodity solutions, today announced a pivotal joint venture with a prestigious Malaysian Agri-processing group to produce and export 180,000 metric tons (MT) of high-grade food-use inputs annually to a key Northeast Asian market. This initiative is strategically designed to align with evolving regional trade policies and leverages Malaysia's unique status under the ASEAN Free Trade Agreement (FTA) for tax-free access to one of the world's largest import markets.
Supply Gaps &amp; Regulatory Adjustments
<ul>
<li>Structural Imbalance: The destination market continues to face a significant supply-demand gap in essential food-use inputs. Annual domestic production is 5 million metric tons short, which is partially supplemented by imports.
<ul>
<li>These imports are strictly controlled under quotas and subject to significant import duties, limiting flexibility and cost efficiency for most suppliers.</li>
<li>Malaysia is currently the sole ASEAN country with unrestricted, tax-free access under the ASEAN Free Trade Agreement (FTA), offering a unique and powerful advantage in reaching the market efficiently.</li>
</ul>
</li>
<li>Policy Recalibration:
<ul>
<li>Neighboring ASEAN countries have recently faced trade restrictions due to compliance and origin-verification issues, effectively reducing their access to the market.</li>
<li>Malaysia's strong regulatory alignment and FTA status position it as the sole viable regional partner for seamless, duty-exempt access to this high-demand market.</li>
</ul>
</li>
</ul>
Market Disruption Creates Opportunity
<ul>
<li>The rapid influx of lower-cost regional inputs in recent years destabilized domestic market pricing, leading to regulatory tightening.</li>
<li>Importing authorities are now focusing on quality-assured, traceable supply from trusted FTA-compliant partners—placing Malaysia at the forefront of future trade.</li>
</ul>
The Joint Venture: DTCK + Malaysian Prestige Agri-Processor
Operational Overview
<ul>
<li>Initial Export Volume: 180,000 MT annually, with scalability plans aligned to market needs and policy evolution. We intend to increase the capacity to 360,000 MT to further enhance our market position.</li>
<li>Facility Location: Port Klang, Malaysia—leveraging existing world-class refining infrastructure.</li>
<li>Capital Deployment:
<ul>
<li>Targeted investment in technology and equipment upgrades.</li>
<li>Flexible working capital structure to match import demand cycles. &nbsp;</li>
</ul>
</li>
</ul>
Competitive Advantages
<ol>
<li>Duty-Free Market Access: Malaysian-origin products enjoy 0% tariff status under FTA, providing a decisive pricing edge over non-member countries subject to import duties exceeding 50%.</li>
<li>Regulatory Compliance: Products are fully aligned with the stringent food-grade standards set by the importing country, unlike regional competitors currently facing partial bans or rejections.</li>
<li>End-to-End Assurance:
<ul>
<li>Davis Commodities' global logistics infrastructure includes expert offices and teams across key international hubs.</li>
<li>Supported by an experienced team with a proven track record in managing over 180,000 MT of agricultural commodities annually, Davis Commodities ensures seamless delivery, real-time traceability, and full documentation compliance from origin to destination.</li>
<li>This robust logistics capability enables the joint venture to meet not just volume requirements but also the strict traceability and anti-dumping standards imposed by regulatory bodies.</li>
</ul>
</li>
</ol>
Market Confidence &amp; Strategic Financial Impact
<ul>
<li>Competitive Landscape: Alternative regional suppliers continue to face compliance hurdles, with a substantial portion of shipments delayed or rejected due to regulatory issues.</li>
<li>DTCK-Malaysia JV Strategic Positioning:
<ul>
<li>Pre-qualified status with government-linked buyers in the target market.</li>
<li>Ability to command premium pricing thanks to FTA alignment, trusted supply chain reputation, and full regulatory certification.</li>
</ul>
</li>
</ul>
Financial Highlights:
<ul>
<li>Revenue Outlook (Year One): Robust top-line performance expected, underpinned by volume contracts and value-added pricing.</li>
<li>Profitability Metrics: EBITDA margins projected to exceed industry benchmarks by a significant margin, reflecting the structural advantages of the JV's trade and production setup.</li>
<li>Revenue Forecast: In the first year, the joint venture is expected to handle 180,000 metric tons, with a projected revenue of USD 117 million, by the second year, the volume is anticipated to double to 360,000 metric tons, resulting in an estimated revenue of USD 234 million. &nbsp;</li>
</ul>

Contracts

DTCK

Davis Commodities Enters Strategic Joint Venture With Malaysian Agri-Processor To Capitalize On Regional Policy Shifts And Secure Preferred Market Access

IONS

Ionis Pharmaceuticals Sees FY2025 Sales $725.000M-$750.000M vs $659.37M Est

The international trade environment has evolved rapidly and is likely to remain dynamic. The Company's estimate of the direct impacts of tariffs is based on rates as of our earnings announcement and does not reflect potential future indirect impacts, including lower demand, which are difficult to predict at this time.

General

Based On Announced Tariffs And Current Market Conditions, Oshkosh Estimates That The Direct Adverse Impact Of Tariffs, Net Of Mitigation Efforts, Could Be In The Range Of $1.00 Per Share For 2025. The Company Anticipates That Company-wide Cost Reduction Actions Will Partially Offset This Impact By Up To $0.50 Per Share.

Vita Coco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCO#NASDAQ">COCO</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.20 by 55 percent. This is a 29.17 percent increase over earnings of $0.24 per share from the same period last year. The company reported quarterly sales of $130.92 million which beat the analyst consensus estimate of $125.49 million by 4.33 percent. This is a 17.21 percent increase over sales of $111.70 million the same period last year.

Vita Coco Q1 GAAP EPS $0.31 Beats $0.20 Estimate, Sales $130.92M Beat $125.49M Estimate

SunCoke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXC#NYSE">SXC</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 13.04 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $436.00 million which beat the analyst consensus estimate of $371.60 million by 17.33 percent. This is a 10.73 percent decrease over sales of $488.40 million the same period last year.

SunCoke Energy Q1 EPS $0.20 Beats $0.17 Estimate, Sales $436.00M Beat $371.60M Estimate

<ul>
<li>Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.</li>
<li>OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.</li>
<li>OKYO Pharma plans for a meeting with FDA following evaluation of clinical data.</li>
</ul>
LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces plans to accelerate the clinical development of urcosimod to treat NCP through the analysis of its data following the early closure of its Phase 2 trial.

OKYO

OKYO Pharma Plans To Accelerate Clinical Development Of urcosimod To Treat NCP Through Data Analysis Following Early Closure Of Phase 2 Trial

Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) affirms FY2025 Adj EPS guidance from $7.80 to $7.80 vs $7.92 analyst estimate. Raises FY2025 sales outlook from $6.80 billion to $6.85 billion vs $6.83 billion estimate.

GRMN

Garmin Affirms FY2025 Adj EPS Guidance of $7.80 vs $7.92 Est; Raises FY2025 Sales Guidance from $6.80B to $6.85B vs $6.83B Est

CHEF

The Chefs' Warehouse Raises FY2025 Sales Guidance from $3.94B-$4.04B to $3.96B-$4.04B vs $4.01B Est

Blackbaud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLKB#NASDAQ">BLKB</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.90 by 6.67 percent. This is a 3.23 percent increase over earnings of $0.93 per share from the same period last year. The company reported quarterly sales of $270.66 million which beat the analyst consensus estimate of $268.18 million by 0.93 percent. This is a 3.08 percent decrease over sales of $279.25 million the same period last year.

Blackbaud Q1 Adj. EPS $0.96 Beats $0.90 Estimate, Sales $270.66M Beat $268.18M Estimate

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is looking for FY2025 GAAP EPS of $(1.60)-$(1.40) vs $(0.61) analyst estimate..

SRDX

Surmodics Sees FY2025 GAAP EPS $(1.60)-$(1.40) vs $(0.61) Est

Ionis Pharmaceuticals Q1 Adj. EPS $(0.93) Beats $(1.12) Estimate, Sales $132.00M Beat $125.32M Estimate

Press Releases

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Comments

Tevogen Bio Holdings

Intérêt court

Tevogen Bio Holdings (NASDAQ:TVGN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL